It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of...more
8/7/2024
/ Delisting ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Inflation Reduction Act (IRA) ,
Manufacturers ,
Orange Book ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Pharmacy Benefit Manager (PBM) ,
Popular ,
Prescription Drugs ,
Robinson-Patman Act
While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations and the first 10 drugs...more
8/30/2023
/ Centers for Medicare & Medicaid Services (CMS) ,
Contract Negotiations ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Excise Tax ,
FTC Act ,
Inflation Reduction Act (IRA) ,
Manufacturers ,
Medicare ,
Medicare Part D ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Preliminary Injunctions ,
Prescription Drugs ,
Section 340B ,
Transparency
States remain at the forefront of legislative efforts on a range of issues relating to drug pricing, such as increasing price transparency, capping out-of-pocket costs for insulin, and limiting certain PBM practices. These...more
9/15/2022
/ Disclosure Requirements ,
Drug Pricing ,
Health Care Providers ,
Manufacturers ,
Medicare Part B ,
Medicare Part D ,
Out-of-Pocket Expenses ,
Pharmaceutical Industry ,
Pharmacies ,
Prescription Drugs ,
Price Transparency ,
Regulatory Agenda ,
Section 340B ,
State and Local Government ,
State Legislatures